SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

The Invesco QQQ Trust is trending as investors grapple with heightened geopolitical volatility following a 48-hour ultimatum issued to Iran, sparking fears of a potential supply disruption in the Strait of Hormuz and a broader escalation in energy prices. Market participants are actively debating whether this represents a transient buying opportunity or the beginning of a deeper structural correction, as community sentiment remains polarized over the impact of ongoing conflict on domestic debt markets and inflationary pressures.

SSgA Active Trust - State Street SPDR S&P 500 ETF Trust

Market sentiment for the S&P 500 is sharply divided as participants brace for increased volatility amid escalating geopolitical tensions in the Middle East and a 48-hour ultimatum impacting global oil supplies. The community is actively debating whether current price action indicates a regime shift toward a deeper bear market or if the persistent dip-buying behavior will once again provide a catalyst for a recovery.

ProShares Trust - ProShares Ultra Bloomberg Natural Gas 2x Shares

ProShares Ultra Bloomberg Natural Gas

ProShares Ultra Bloomberg Natural Gas (BOIL) is currently experiencing intense volatility as traders debate the disconnect between escalating Middle East geopolitical risks and stagnant domestic price action. The community remains sharply divided, with bulls pointing to potential supply disruptions in the Strait of Hormuz and infrastructure damage as catalysts for a squeeze, while bears highlight significant contango-driven decay and seasonal shoulder-season demand weakness.

iShares Silver Trust - Fractional undivided beneficial interests

iShares Silver Trust

iShares Silver Trust is experiencing intense volatility as investors debate whether the recent sharp price decline is a structural liquidation or a strategic buying opportunity amid rising geopolitical tensions and inflationary concerns. The community remains deeply divided, with many traders actively discussing potential COMEX supply constraints and institutional manipulation, while others warn of further downside risks as the asset struggles to maintain its historical safe-haven status.

Robinhood Markets, Inc is a financial services platform, which engages in the provision of retail brokerage and offers trading in U.S. listed stocks and Exchange Traded Funds, related options, and cryptocurrency trading, as well as cash management, which includes debit cards services. The company was founded by Vladimir Tenev and Baiju Prafulkumar Bhatt in 2013 and is headquartered in Menlo Park, CA.

Robinhood Markets Inc - Ordinary Shares - Class A

Robinhood Markets Inc

Robinhood (HOOD) is trending as investors debate the stock's long-term potential following a significant correction and its heavy correlation with crypto market volatility. While some community members see the current price as a value opportunity supported by new product rollouts like social trading, others are concerned by regulatory headlines and the stock's persistent weakness compared to broader market indices.

ProShares Trust - ProShares UltraShort Bloomberg Natural Gas -2x Shares

ProShares UltraShort Bloomberg Natural Gas

KOLD is trending as investors weigh volatile geopolitical risks in the Middle East against bearish seasonal fundamentals like rising production and the approaching shoulder season. The community is actively debating whether ongoing tensions and potential maritime disruptions will provide a lasting floor for prices or if the expected inventory builds will ultimately drive a sharp downward reversal.

T-Mobile US, Inc. engages in the provision of wireless communications services under the T-Mobile and MetroPCS brands. It offers postpaid and prepaid wireless voice, messaging and data services, and wholesale wireless services. The company was founded in 1994 and is headquartered in Bellevue, WA.

T-Mobile US Inc

T-Mobile US is capturing market attention as investors weigh its competitive positioning in 5G and satellite integration against broader sector-wide pricing pressures and technical consolidation. While some community members remain focused on long-term growth potential and recent institutional accumulation, others are debating the impact of increased industry competition on its forward performance.

Bitcoin Cash is a hard fork of Bitcoin with a protocol upgrade to fix on-chain capacity. Bitcoin Cash intends to be a Bitcoin without Segregated Witness (SegWit) as soft fork, where upgrades of the protocol are done mainly through hard forks and without changing the original economic rules of the Bitcoin.  Bitcoin Cash (BCH) is released on 1st August 2017 as an upgraded version of the original Bitcoin Core software. The main upgrade is the increase in the block size limit from 1MB to 8MB. This effectively allows miners on the BCH chain to process up to 8 times more payments per second in comparison to Bitcoin. This makes for faster, cheaper transactions and a much smoother user experience.  Why was Bitcoin Cash Created?  The main objective of Bitcoin Cash is to to bring back the essential qualities of money inherent in the original Bitcoin software. Over the years, these qualities were filtered out of Bitcoin Core and progress was stifled by various people, organizations, and companies involved in Bitcoin protocol development. The result is that Bitcoin Core is currently unusable as money due to increasingly high fees per transactions and transfer times taking hours to complete. This is all because of the 1MB limitation of Bitcoin Core’s block size, causing it unable to accommodate to large number of transactions.  Essentially Bitcoin Cash is a community-activated upgrade (otherwise known as a hard fork) of Bitcoin that increased the block size to 8MB, solving the scaling issues that plague Bitcoin Core today.  Nov 16th 2018: A hashwar resulted in a split between Bitcoin SV and Bitcoin ABC

Bitcoin Cash

Bitcoin Cash is capturing significant community attention as it displays resilience and outperformance compared to major counterparts, with many traders closely monitoring its consolidation near key resistance levels. Speculation is mounting that the asset is poised for a potential breakout, driven by anticipation of upcoming network upgrades and whale accumulation.

JasmyCoin is based on the ERC 20 standard. The token can also be used by an unspecified number of individuals and businesses to transfer tokens using digital devices as proof of value exchange or payment for services. By not limiting its usability, the token can have a wide range of purposes.

JasmyCoin

JasmyCoin is currently facing intense scrutiny as community sentiment shifts toward skepticism, with investors debating its long-term viability against competing projects like Janction. While some retail traders remain committed to accumulating through ongoing volatility, others are increasingly vocal about their frustration regarding lack of price momentum and perceived lack of transparency from the leadership team.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is currently experiencing intense volatility as market participants weigh geopolitical threats in the Middle East against ongoing institutional accumulation and macroeconomic pressures. The community remains deeply divided, with bearish traders citing potential capitulation and historical cycle patterns, while bullish proponents view the current price action as a short-term shakeout driven by leveraged liquidations.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Soligenix Announces HyBryte Clinical Summary Published in "Expert Opinion on Investigational Drugs"

Soligenix Announces HyBryte Clinical Summary Published in 'Expert Opinion on Investigational Drugs' Soligenix Announces HyBryte Clinical Summary Published in 'Expert Opinion on Investigational Drugs...

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency

Soligenix Announces SGX945 Receives Promising Innovative Medicine Designation from the UK Medicines and Healthcare Products Regulatory Agency Soligenix Announces SGX945 Receives Promising Innovative...

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease

Soligenix Receives Positive Opinion from the European Medicines Agency on the Request for Orphan Drug Designation for SGX945 for the Treatment of Behet's Disease Soligenix Receives Positive Opinion...

Soligenix to Present at BIO Investment & Growth Summit

Soligenix to Present at BIO Investment & Growth Summit Soligenix to Present at BIO Investment & Growth Summit PR Newswire PRINCETON, N.J., Feb. 24, 2026 PRINCETON, N.J., Feb. 24, 2026 /PRNewswire...

Soligenix Details Recent Progress and Upcoming Milestones

Soligenix Details Recent Progress and Upcoming Milestones Soligenix Details Recent Progress and Upcoming Milestones PR Newswire PRINCETON, N.J., Feb. 12, 2026 PRINCETON, N.J., Feb. 12, 2026...

Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel

Soligenix reports positive Phase 2a extension results for SGX302 gel in psoriasis, showing improved skin scores and strong tolerability.read more...

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis

Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis Soligenix Announces Top-line Results of the Phase 2a Study of...

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma

Soligenix Achieves Enrollment Milestone for Planned Interim Analysis in Confirmatory Phase 3 Clinical Trial of HyBryte for the Treatment of Cutaneous T-Cell Lymphoma Soligenix Achieves Enrollment...

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma

Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma PR Newswire PRINCETON, N.J...

Shares of Soligenix rallied sharply on Tuesday, marking their best performance in nearly two months, after the biopharmaceutical company reported a key safety milestone in its confirmatory Phase 3 FLASH2 trial evaluating HyBryte (synthetic hypericin) for treating cutaneous T-cell lymphoma (CTCL).The stock jumped 20% to $1.64 on Tuesday, and added another 0.9% after hours in continued upbeat trading.The company said its first Data Monitoring Committee (DMC) meeting for the study concluded that there were no safety concerns, with HyBryte’s safety profile consistent with prior trials.&nbsp;The committee’s conclusion allows the trial to move ahead as planned, with enrollment proceeding well and an update expected in the fourth quarter of 2025, followed by a blinded interim efficacy analysis in the first half of 2026.The ongoing FLASH2 trial is a randomized, double-blind, placebo-controlled, multicenter study enrolling about 80 patients with early-stage CTCL. The study builds on Soligenix’s previous successful Phase 3 FLASH trial, which showed a 49% treatment response after 18 weeks of therapy.&nbsp;FLASH2 extends continuous double-blind treatment to 18 weeks, designed to demonstrate the drug’s effect over a more “real-world” course.HyBryte, which uses visible light-activated synthetic hypericin applied topically to skin lesions, has received orphan drug and fast-track designations from the FDA, along with&nbsp;an orphan designation from the European Medicines Agency (EMA). The company stated that its light-activated mechanism enables deeper penetration into skin tissue without causing DNA damage, positioning it as a potentially safer frontline therapy for CTCL.On Stocktwits, retail sentiment for Soligenix was ‘extremely bullish’ amid a 2,025% surge in 24-hour message volume.One bullish user described the latest Soligenix update as a strong catalyst, saying the stock appeared ready to rebound sharply after the morning dip and could test new highs in the coming sessions.&nbsp;<stembedurl>https://stocktwits.com/LithiumMakesMeHard/message/631396013</stembedurl>Another bullish user noted that the price action suggested momentum might continue, with potential for a multiday run.<stembedurl>https://stocktwits.com/bzspy/message/631352248</stembedurl><a href="https://stocktwits.com/symbol/SNGX">Soligenix’s stock</a> has declined 39% so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Soligenix’s stock (SNGX) has declined 39% so far in 2025. (Photo credit: Getty Images)

Soligenix Logs Best Session In Nearly 2 Months After Safety Win In T-Cell Lymphoma Trial — Traders Eye Multiday Rally

The company said enrollment in its Phase 3 HyBryte study is progressing well, with an interim efficacy analysis planned for the first half of 2026. 

Equity

Soligenix, Inc. is a late-stage biopharmaceutical company, which engages in the development and commercialization of products to treat rare diseases. It operates through the Specialized BioTherapeutics and Public Health Solutions segments. The Specialized BioTherapeutics segment focuses on the development of a novel photodynamic therapy (SGX301) utilizing topical synthetic hypericin activated with safe visible fluorescent light for the treatment of cutaneous T-cell lymphoma. The Public Health Solutions segment consists of active development programs for RiVax, a ricin toxin vaccine candidate, and SGX943, a therapeutic candidate for antibiotic resistant and emerging infectious disease. The company was founded in 1987 and is headquartered Princeton, NJ.

Current Price	$1.20
Prev Close	$1.22
Open	$1.23
Dividend Yield	0.00%
50-Day Moving Average	$1.23
Beta	0.55
Avg. Volume	153,156.03
PE Ratio	-0.33

52-Week High	$6.23
52-Week Low	$1.02
Market Capitalization	$12.1M
EPS (Annual)	-$4.98
Price to Book	1.56
Revenue Per Employee	$0.00

SNGX
Soligenix Inc

Feed

News

Sentiment

Fundamentals

Info

Latest SNGX News

SNGXSoligenix Inc